← Cardiff Oncology, Inc. (CRDF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cardiff Oncology, Inc. (CRDF)
Biological Products, (No Diagnostic Substances) · market cap $103M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cardiff Oncology (CRDF) is a clinical-stage oncology company with a pipeline of Phase 2 assets, most notably onvansertib combined with FOLFIRI/FOLFOX in metastatic colorectal cancer and cytarabine in AML. With a $92M market cap, only $8.5M in cash (~2.1 months of runway), and a burn rate implying roughly $40M+ annually in net losses, the company faces an acute near-term financing crisis that overshadows any pipeline optionality.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Onvansertib | Phase 2 | Colorectal Cancer |
| Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma |
Price & technical context
3-month
-12.3%
6-month
-27.8%
12-month
-45.2%
52-wk range
$0.81–$3.21
vs 50-day MA
+7.3%
vs 200-day MA
-29.9%
Realized vol
91.6%
Max drawdown
-84.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRDF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.